Qureator is proud to announce its selection as a shortlisted finalist for the renowned Lush Prize in the Science category. This prestigious initiative awards £50,000 to projects that drive the transition toward practical, regulator-accepted non-animal testing methods.
View the full shortlist: https://lushprize.org/2026-prize/2026-prize-shortlist/
Qureator Appoints Paul Park as Consulting Chief Business Officer
We are thrilled to welcome Paul Park to Qureator as our new Consulting CBO. Paul brings over 20 years of executive experience from Amgen, Ionis, and Circle Pharma, with a proven track record in strategy, M&A, and high-impact partnerships.
Following a landmark FDA IND approval that validated its animal-free vTIME platform, Qureator is launching new anti–PD-1/L1 and PD-1/VEGF bispecific campaigns with a special, limited-time offer for partners.
Qureator announced the world’s first FDA Investigational New Drug (IND) approval for an oncology therapy, SillaJen’s BAL0891, based solely on efficacy data from our human vascularized organ-on-a-chip (vTIME) platform, successfully replacing traditional animal studies.
The FDA’s recent decision to phase out mandatory animal testing marks a historic shift in drug development — and Qureator is ready. From the start, Qureator has championed human-relevant, next-generation platforms that better bridge lab models to patient outcomes.
Qureator is thrilled to announce the appointment of Dr. Branka Mitrovic, a distinguished leader in translational research and therapeutic innovation.
Qureator proudly announces the promotion of Dr. Tsung-li Liu to Chief Technology Officer (CTO).